Mirum Pharmaceuticals, Inc. MIRM

89.70 0.34 0.38% as of 25 Sep
Market cap
$5.8B
P/E
0.0×
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(15.81%) (8.65%) (335.82%) (702.97%)
ROA
(5.70%) (3.09%) (101.04%) (97.15%)
ROIC
(11.56%) (5.74%) (298.98%) (172.96%)
Return on Tangible Assets
(11.15%) (6.76%) (267.15%) (206.89%)
Average Days of Receivables
82.88 86.35 85.30 85.84
Free Cash Flow per Share
0.88 1.09 (3.44) (4.32)
Free Cash Flow
44.32 54.87 (202.55) (273.74)
Capital Expenditures
(0.37) (0.95) (31.58) (46.47)
Piotroski F-Score
6.00 6.00 4.00 3.00
Other line items
Cash ROIC
4.57% 5.54% (18.21%) (19.29%)
Accounts Receivable Turnover
5.37 5.17 4.98 4.90
Accounts Payable Turnover
8.73 8.27 2.99 5.50
Inventory Turnover
4.15 4.24 4.42 4.64
Average Days of Payables
46.87 35.01 204.48 75.70
Days of Inventory on Hand
92.53 90.62 87.85 83.27
Tax Rate
0.01 0.09 0.00 0.00
Research and Development Expense of Revenue
37.96% 35.71% 169.30% 165.88%
Selling, General and Administrative Expense of Revenue
50.81% 49.30% 51.90% 50.78%
Share Based Compensation of Revenue
13.91% 13.70% 16.12% 16.82%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
(1.08) (2.39) 0.21 0.26
Depreciation/Fixed assets
20.32 13.95 11.12 12.41
Capex/Depreciation
(0.01) (0.04) (1.18) (1.66)
Revenue per Share
9.32 10.39 9.68 9.75
Operating CF per Share
0.88 1.11 (2.91) (3.59)
Capex per Share
(0.01) (0.02) (0.54) (0.73)
Capex to Sales
0.00 0.00 0.06 0.08
Net Profit Margin
(8.78%) (4.48%) (140.24%) (139.18%)

Fold the line items

Columns are period end dates